Atovaquone and Proguanil Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

Million

Market Dynamics of Atovaquone and Proguanil Market Analysis

Growth Drivers

  • Rising Malaria Incidence & Travel Prophylaxis Needs
  • Government and Nonprofit Assistance for Malaria Prevention Initiatives
  • Generics' accessibility and the growth of reasonably priced formulations

Restraints

  • Low-Income Areas' Uptake Is Restricted by High Treatment Costs
  • Drug Resistance and Declining Efficacy
  • Regulatory Barriers and Product Quality Risks

Trends

  • Transition to Lower-Dosage and Pediatric Formats
  • Regional Growth in Asia-Pacific and Europe
  • Innovation in Delivery Models and Formulations

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Atovaquone and Proguanil Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Atovaquone and Proguanil Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Global$ 145.5 Million$ 225.7 Million$ 543.06 Million11.6%
North America$ 49.8 Million$ 75.6 Million$ 178.1 Million11.3%
United States$ 37.3 Million$ 56.3 Million$ 131.8 Million11.2%
Canada$ 7.5 Million$ 11.7 Million$ 28.5 Million11.7%
Mexico$ 5 Million$ 7.6 Million$ 17.8 Million11.3%
Europe$ 41.3 Million$ 63.5 Million$ 151.5 Million11.5%
United Kingdom$ 7.4 Million$ 11.3 Million$ 26.5 Million11.3%
France$ 6.4 Million$ 9.8 Million$ 23.2 Million11.4%
Germany$ 9.1 Million$ 14 Million$ 33.6 Million11.5%
Italy$ 4.3 Million$ 6.7 Million$ 16.2 Million11.6%
Russia$ 3.3 Million$ 5 Million$ 11.8 Million11.3%
Spain$ 2.9 Million$ 4.6 Million$ 11.4 Million12%
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourg$ 1 Million$ 1.5 Million$ 3.3 Million10.6%
Rest of Europe$ 4.5 Million$ 7.1 Million$ 17.3 Million11.7%
Asia Pacific$ 32.7 Million$ 53.4 Million$ 134.7 Million12.3%
China$ 9.8 Million$ 16.8 Million$ 44.4 Million12.9%
Japan$ 6.5 Million$ 10.1 Million$ 24.2 Million11.5%
South Korea$ 3.3 Million$ 5.1 Million$ 12.1 Million11.5%
India$ 4.9 Million$ 9.3 Million$ 26.9 Million14.2%
Australia$ 1.6 Million$ 2.9 Million$ 8.1 Million13.5%
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asia$ 3.3 Million$ 4.8 Million$ 10.8 Million10.6%
Rest of APACxxxxxxxxxxxx13.3%
South Americaxxxxxxxxxxxx10.9%
Brazil$ 5.5 Million$ 8.5 Million$ 20.4 Million11.6%
Argentina$ 2.8 Million$ 4.6 Million$ 11.8 Million12.6%
Colombia$ 2.1 Million$ 3.4 Million$ 8.6 Million12.4%
Peru$ 1.4 Million$ 2.2 Million$ 5.6 Million12.3%
Chile$ 0.7 Million$ 1.2 Million$ 3.2 Million13.1%
Rest of South Americaxxxxxxxxxxxx10%
Middle Eastxxxxxxxxxxxx11.2%
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkey$ 0.8 Million$ 1.3 Million$ 3 Million11.5%
UAExxxxxxxxxxxxxxxx
Egypt$ 1.6 Million$ 2.4 Million$ 5.5 Million11%
Qatarxxxxxxxxxxxxxxxx
Rest of Middle East$ 0.4 Million$ 0.4 Million$ 0.5 Million2.9%
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Atovaquone and Proguanil Market Type Segment Analysis According to Cognitive Market Research, 250 mg/100 mg stands out as the dominating category. The 250 mg/a hundred mg method of Atovaquone and Proguanil is contributing to the increase of the market by means of supplying a handy and effective dosage option for malaria prevention and treatment. This unique formula is favored for its simplicity and efficacy, attracting travelers and healthcare vendors alike in regions in which malaria is a conventional issue. 62.5mg/25mg emerges as the fastest-growing category in the Atovaquone and Proguanil market. The 62. Five mg/25 mg formulation of Atovaquone and Proguanil is increasing the marketplace by means of supplying a decrease-dose option suitable for pediatric and smaller person populations. This method meets specific dosage wishes while preserving effectiveness in malaria prevention and treatment. Its availability helps broader accessibility and adherence amongst numerous patient demographics, contributing to the general increase of Atovaquone and Proguanil usage globally.

250 mg/100 mg Atovaquone and Proguanil Market Analysis
XX
250 mg/100 mg Market Size 2025
XX %
CAGR
Locked · Full data in paid report
62.5mg/25mg Atovaquone and Proguanil Market Analysis
XX
62.5mg/25mg Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape of the Atovaquone and Proguanil Market

The competitive landscape of the Atovaquone and Proguanil market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established electronics manufacturers, specialized Atovaquone and Proguanil companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
GSK••• ••• ••• •••
Glenmark••• ••• ••• •••
Mylan Pharmaceuticals••• ••• ••• •••
Hetero.••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the global Atovaquone and Proguanil market size is USD 185.6 million in 2024. It will expand at a compound annual growth rate (CAGR) of 11.50% from 2024 to 2031.

  • North America held the major market share for more than 40% of the global revenue with a market size of USD 74.24 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.
  • Europe accounted for a market share of over 30% of the global revenue with a market size of USD 55.68 million.
  • Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 42.6 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2031.
  • Latin America had a market share for more than 5% of the global revenue with a market size of USD 9.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2031.
  • Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 3.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.
  • The 250 mg/100 mg held the highest Atovaquone and Proguanil market revenue share in 2024.

 

Introduction of the Atovaquone and Proguanil Market

Atovaquone and proguanil, advertised together as an aggregate drug (atovaquone/proguanil), are broadly used for each malaria prevention and remedy. Atovaquone objectives the malaria parasite's mitochondria, disrupting its electricity production, while proguanil inhibits parasite DNA synthesis. This aggregate is effective towards each Plasmodium falciparum and Plasmodium vivax malaria trace. In the market, atovaquone/proguanil is available below various emblem names globally and is suggested for tourists to malaria-endemic areas. The drug's comfort in being taken as soon as daily and its enormously suitable tolerability profile make it a favored preference for many vacationers. However, side results such as nausea, vomiting, and diarrhea can occur.

Analyst Conclusion

  • The global Atovaquone and Proguanil market will expand significantly by 11.50% CAGR between 2024 to 2031.
  • The surge in e-commerce has increased demand for quicker and more effective order fulfillment. ASRS is essential to these activities because it makes it easier to quickly pick and send out a large range of things.
  • More complex and intelligent ASRS solutions are being produced as a result of advances in control systems, robotics, and artificial intelligence. These developments enhance functionality overall, precision, and flexibility.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

The global market size for Atovaquone and Proguanil in 2024 is USD 185.6 million.
The global Atovaquone and Proguanil market is expected to grow with a CAGR of 11.50% over the projected period.
North America held a significant global Atovaquone and Proguanil market revenue share in 2024.
Europe will witness the fastest growth of the global Atovaquone and Proguanil market over the coming years.
The US had the most significant global Atovaquone and Proguanil market revenue share in 2024.
The main drivers of the growth of the Atovaquone and Proguanil market are Rising Malaria Burden, Increased Travel and Migration and Drug Resistance Concerns.
The 250 mg/100 mg segment had the largest share in the global Atovaquone and Proguanil market by Type.

★ Reviews

Rate this report

Atovaquone and Proguanil Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Type250 mg/100 mg, 62.5mg/25mg
ApplicationAdult, Paediatric
List of CompetitorsGSK, Glenmark, Mylan Pharmaceuticals, Hetero.

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Atovaquone and Proguanil Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 GSK
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Glenmark
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Mylan Pharmaceuticals
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Hetero.
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 Financials (Subject to data availability)
        • 1.2.4.4 R&D Investment (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis

  • Chapter 2. Global Atovaquone and Proguanil Market Analysis

    • 2.1 Global Atovaquone and Proguanil Market Analysis
    • 2.2 Global Atovaquone and Proguanil Market Analysis by Region
    • 2.3 Global Atovaquone and Proguanil Market Analysis by Type
    • 2.4 Global Atovaquone and Proguanil Market Analysis by Application
    • 2.5 Global Atovaquone and Proguanil Market Analysis by Key Players

  • Chapter 3. North America Atovaquone and Proguanil Market Analysis

    • 3.1 North America Atovaquone and Proguanil Market Analysis
    • 3.2 North America Atovaquone and Proguanil Market Analysis by Country
    • 3.3 North America Atovaquone and Proguanil Market Analysis by Type
    • 3.4 North America Atovaquone and Proguanil Market Analysis by Application
    • 3.5 North America Atovaquone and Proguanil Market Analysis by Key Players

  • Chapter 4. Europe Atovaquone and Proguanil Market Analysis

    • 4.1 Europe Atovaquone and Proguanil Market Analysis
    • 4.2 Europe Atovaquone and Proguanil Market Analysis by Country
    • 4.3 Europe Atovaquone and Proguanil Market Analysis by Type
    • 4.4 Europe Atovaquone and Proguanil Market Analysis by Application
    • 4.5 Europe Atovaquone and Proguanil Market Analysis by Key Players

  • Chapter 5. Asia Pacific Atovaquone and Proguanil Market Analysis

    • 5.1 Asia Pacific Atovaquone and Proguanil Market Analysis
    • 5.2 Asia Pacific Atovaquone and Proguanil Market Analysis by Country
    • 5.3 Asia Pacific Atovaquone and Proguanil Market Analysis by Type
    • 5.4 Asia Pacific Atovaquone and Proguanil Market Analysis by Application
    • 5.5 Asia Pacific Atovaquone and Proguanil Market Analysis by Key Players

  • Chapter 6. South America Atovaquone and Proguanil Market Analysis

    • 6.1 South America Atovaquone and Proguanil Market Analysis
    • 6.2 South America Atovaquone and Proguanil Market Analysis by Country
    • 6.3 South America Atovaquone and Proguanil Market Analysis by Type
    • 6.4 South America Atovaquone and Proguanil Market Analysis by Application
    • 6.5 South America Atovaquone and Proguanil Market Analysis by Key Players

  • Chapter 7. Middle East Atovaquone and Proguanil Market Analysis

    • 7.1 Middle East Atovaquone and Proguanil Market Analysis
    • 7.2 Middle East Atovaquone and Proguanil Market Analysis by Country
    • 7.3 Middle East Atovaquone and Proguanil Market Analysis by Type
    • 7.4 Middle East Atovaquone and Proguanil Market Analysis by Application
    • 7.5 Middle East Atovaquone and Proguanil Market Analysis by Key Players

  • Chapter 8. Africa Atovaquone and Proguanil Market Analysis

    • 8.1 Africa Atovaquone and Proguanil Market Analysis
    • 8.2 Africa Atovaquone and Proguanil Market Analysis by Country
    • 8.3 Africa Atovaquone and Proguanil Market Analysis by Type
    • 8.4 Africa Atovaquone and Proguanil Market Analysis by Application
    • 8.5 Africa Atovaquone and Proguanil Market Analysis by Key Players

  • Chapter 9. Type Analysis

    • 9.1 250 mg/100 mg
      • 9.1.1 Global 250 mg/100 mg Market
      • 9.1.2 Global 250 mg/100 mg Market by Region
    • 9.2 62.5mg/25mg
      • 9.2.1 Global 62.5mg/25mg Market
      • 9.2.2 Global 62.5mg/25mg Market by Region

  • Chapter 10. Application Analysis

    • 10.1 Adult
      • 10.1.1 Global Adult Market
      • 10.1.2 Global Adult Market by Region
    • 10.2 Paediatric
      • 10.2.1 Global Paediatric Market
      • 10.2.2 Global Paediatric Market by Region

  • Chapter 11. Qualitative Analysis (Subject to Data Availability)

    • 11.1 Market Drivers
    • 11.2 Market Restraints
    • 11.3 Market Trends
    • 11.4 Market Opportunity
    • 11.5 Technological Road Map (Subject to Data Availability)
    • 11.6 Product Life Cycle (Subject to Data Availability)
    • 11.7 Customer and Buyer Behavior Analysis
      • 11.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 11.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 11.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 11.7.4 Pricing, Affordability & Value Perception Analysis
      • 11.7.5 Customer Segmentation & Demand Pattern Analysis
    • 11.8 PESTEL Analysis
      • 11.8.1 Political Factors
      • 11.8.2 Economic Factors
      • 11.8.3 Social Factors
      • 11.8.4 Technological Factors
      • 11.8.5 Legal Factors
      • 11.8.6 Environmental Factors
    • 11.9 Industrial Chain Analysis (Subject to Data Availability)
      • 11.9.1 Industry Chain Analysis
      • 11.9.2 Manufacturing Cost Analysis
      • 11.9.3 Supply Side Analysis
        • 11.9.3.1 Raw Material Analysis
        • 11.9.3.2 Raw Material Procurement Analysis
        • 11.9.3.3 Raw Material Price Trend Analysis
    • 11.10 Porter’s Five Forces Analysis
      • 11.10.1 Bargaining Power of Suppliers
      • 11.10.2 Bargaining Power of Buyers
      • 11.10.3 Threat of New Entrants
      • 11.10.4 Threat of Substitutes
      • 11.10.5 Degree of Competition
    • 11.11 Patent Analysis (Subject to Data Availability)
    • 11.12 ESG Analysis
    • 11.13 Geopolitical Outlook
      • 11.13.1 Global Power Realignment & Strategic Alliances
      • 11.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 11.13.3 International Trade Relations & Market Access Environment
      • 11.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 11.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 11.13.6 Technology Sovereignty & Digital Geopolitics
      • 11.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 11.14 AI & Market Transformation
      • 11.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 11.14.2 AI-Driven Transformation of Industry Value Chain
      • 11.14.3 Evolution of Business Models & Revenue Streams
      • 11.14.4 AI-Driven Product, Service & Innovation Transformation
      • 11.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 12. TOP 10 Country Analysis

    • 12.1 Country 1
    • 12.2 Country 2
    • 12.3 Country 3
    • 12.4 Country 4
    • 12.5 Country 5
    • 12.6 Country 6
    • 12.7 Country 7
    • 12.8 Country 8
    • 12.9 Country 9
    • 12.10 Country 10

  • Chapter 13. Research Findings

    • 13.1 Key Takeaways
    • 13.2 Analyst Point of View
    • 13.3 Assumptions and Acronyms

  • Chapter 14. Research Methodology and Sources

    • 14.1 Primary Data Collection
      • 14.1.1 Steps for Primary Data Collection
        • 14.1.1.1 Identification of KOL
      • 14.1.2 Backward Integration
      • 14.1.3 Forward Integration
      • 14.1.4 How Primary Research Help Us
      • 14.1.5 Modes of Primary Research
    • 14.2 Secondary Research
      • 14.2.1 How Secondary Research Help Us
      • 14.2.2 Sources of Secondary Research
    • 14.3 Data Validation
      • 14.3.1 Data Triangulation
    • 14.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Atovaquone and Proguanil Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 4+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Atovaquone and Proguanil Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the atovaquone and proguanil market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.